Literature DB >> 7886091

Nicotine reverses scopolamine-induced impairment of performance in passive avoidance task in rats through its action on the dopaminergic neuronal system.

A Nitta1, Y Katono, A Itoh, T Hasegawa, T Nabeshima.   

Abstract

Interest has recently focused on tobacco and/or nicotine in relation to senile dementia of the Alzheimer type because the population of patients with this disease among tobacco smokers is significantly smaller than in nonsmokers. We investigated whether, in relation to the dopaminergic neuronal system, nicotine was effective in ameliorating the impairment of performance in passive avoidance tasks in rats induced by scopolamine, an inhibitor of muscarinic acetylcholine receptors. Scopolamine and nicotine were coadministered to rats 30 min before the acquisition trial. Some rats received scopolamine alone; they showed much shorter step-through latency (STL) than the control group in the retention test. Nicotine significantly prolonged the decreased STL induced by scopolamine. The effects of nicotine were inhibited by the preadministration of mecamylamine, SCH 23390, and (-)sulpiride, which are nicotinic acetylcholine, D1, and D2 receptor antagonists, respectively. These results suggest that nicotine, by activating the nicotinic acetylcholinergic and dopaminergic neuronal systems, ameliorates the impairment of performance in the passive avoidance task induced by a muscarinic acetylcholine receptor blocker.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7886091     DOI: 10.1016/0091-3057(94)90227-5

Source DB:  PubMed          Journal:  Pharmacol Biochem Behav        ISSN: 0091-3057            Impact factor:   3.533


  4 in total

Review 1.  Epidemiology of the dementias: recent developments and new approaches.

Authors:  C M van Duijn
Journal:  J Neurol Neurosurg Psychiatry       Date:  1996-05       Impact factor: 10.154

Review 2.  Nicotinic system involvement in Alzheimer's and Parkinson's diseases. Implications for therapeutics.

Authors:  P A Newhouse; A Potter; E D Levin
Journal:  Drugs Aging       Date:  1997-09       Impact factor: 3.923

Review 3.  Potential Use of Nicotinic Receptor Agonists for the Treatment of Chemotherapy-Induced Cognitive Deficits.

Authors:  Rex M Philpot
Journal:  Neurochem Res       Date:  2015-02-05       Impact factor: 3.996

Review 4.  Modeling Alzheimer's disease in transgenic rats.

Authors:  Sonia Do Carmo; A Claudio Cuello
Journal:  Mol Neurodegener       Date:  2013-10-25       Impact factor: 14.195

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.